References
- Martin W. R., Jasinski D., Mansky P. Naltrexone, an antagonist for the treatment of heroin dependence. Arch. Gen. Psychiatry 1973; 23: 784–791
- Resnick R., Volavka J., Freedman A. M., et al. Studies on EN-1639-A (naltrexone): A new narcotic antagonist. Am. J. Psychiatry 1974; 131: 646–650
- O'Brien C., Greenstein R., Mintz J., et al. Clinical experience with naltrexone. Am. J. Drug Alcohol Abuse 1975; 2(3–4)365–377
- Wikler A. Dynamics of drug dependence: Implications of a conditioning theory for research and treatment. Arch. Gen. Psychiatry 1973; 28: 611–616
- O'Brien C., Greenstein R., Ternes J., . Clinical pharmacology of narcotic antagonists. Recent Developments in Chemotherapy of Narcotic Addiction, B. Kissin, J. Lowinson, R. Millman, et al. New York Academy of Sciences, New York 1978; 232–240
- Blachly P. Naloxone for diagnosis in methadone programs. J. Am. Med. Assoc. 1973; 224: 334–335
- Sells S., Demaree R., Simpson D., . Evaluation of present treatment modalities: Research with DARP admissions, 1969–1973. Recent Developments in Chemotherapy of Narcotic Addiction, B. Kissen, J. Lowinson, R. Millman, et al. New York Academy of Sciences, New York 1978; 270–281
- Resnick R., Schuyten-Resnick E., Washton A. Narcotic antagonists in the treatment of opioid dependence: Review and commentary. Compr. Psychiatry 1979; 20(2)116–125
- Grabowski J., O'Brien C., Greenstein R., et al. Effects of contingent payment on compliance with a naltrexone regimen. Am. J. Drug Alcohol Abuse 1979; 6(3)355–365
- Resnick R., Washton A. Clinical outcome with naltrexone. Recent Developments in Chemotherapy of Narcotic Addiction, B. Kissin, J. Lowinson, R. Millman. New York Academy of Sciences, New York 1978; 241–247
- Greenstein R., O'Brien C., Mintz J., et al. Clinical Experience with Naltrexone in a Behavioral Research Study: An Interim Report. Research Monograph Series 9, National Institute on Drug Abuse, Naltrexone 1976; 141–149, Narcotic Antagonists